Neoadjuvant pembrolizumab achieved a 71% pCR rate in desmoplastic melanoma, surpassing expectations for neoadjuvant anti–PD-1 treatment. The 3-year relapse-free survival rate was 74%, and the overall ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results